Re: Prognostic Significance of Digital Rectal Examination and Prostate Specific Antigen in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Arm

EDITORIAL COMMENT The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial is a large population-based randomized trial designed and sponsored by the National Cancer Institute to determine the effects of screening on cancer-related mortality and secondary endpoints in men and wome...

Full description

Bibliographic Details
Main Author: Özgür Yaycıoğlu
Format: Article
Language:English
Published: Galenos Yayinevi 2017-03-01
Series:Journal of Urological Surgery
Online Access:http://jurolsurgery.org/article_14738/Re-Prognostic-Significance-Of-Digital-Rectal-Examination-And-Prostate-Specific-Antigen-In-The-Prostate-Lung-Colorectal-And-Ovarian-plco-Cancer-Screening-Arm
_version_ 1797923570324602880
author Özgür Yaycıoğlu
author_facet Özgür Yaycıoğlu
author_sort Özgür Yaycıoğlu
collection DOAJ
description EDITORIAL COMMENT The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial is a large population-based randomized trial designed and sponsored by the National Cancer Institute to determine the effects of screening on cancer-related mortality and secondary endpoints in men and women aged 55 to 74 years. The prostate component of the PLCO trial was undertaken to determine whether there is a reduction in prostate cancer mortality with screening using serum prostate-specific antigen (PSA) testing and digital rectal examination (DRE). The absence of benefit of population-based screening influenced the subsequent U.S. Preventive Services Task Force (USPSTF) recommendation against routine PSA screening. The USPSTF did not address DRE. Therefore, the authors have evaluated the prognostic value of abnormal DRE and PSA following the widespread use of PSA testing. They assessed the association of suspicious DRE and abnormal PSA with the detection of clinically significant prostate cancer, prostate cancer mortality and overall mortality. The data showed that suspicious DRE and abnormal PSA were significantly associated with clinically significant prostate cancer. There was only moderate agreement between PSA and DRM in each screening encounter. The authors emphasized the continued role of DRE and PSA and need for additional research to optimize screening protocols.
first_indexed 2024-04-10T14:49:31Z
format Article
id doaj.art-e28cf64f90654ee1b906e787e14b4750
institution Directory Open Access Journal
issn 2148-9580
language English
last_indexed 2024-04-10T14:49:31Z
publishDate 2017-03-01
publisher Galenos Yayinevi
record_format Article
series Journal of Urological Surgery
spelling doaj.art-e28cf64f90654ee1b906e787e14b47502023-02-15T16:07:41ZengGalenos YayineviJournal of Urological Surgery2148-95802017-03-0141414110.4274/jus.2017.04.007Re: Prognostic Significance of Digital Rectal Examination and Prostate Specific Antigen in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening ArmÖzgür YaycıoğluEDITORIAL COMMENT The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial is a large population-based randomized trial designed and sponsored by the National Cancer Institute to determine the effects of screening on cancer-related mortality and secondary endpoints in men and women aged 55 to 74 years. The prostate component of the PLCO trial was undertaken to determine whether there is a reduction in prostate cancer mortality with screening using serum prostate-specific antigen (PSA) testing and digital rectal examination (DRE). The absence of benefit of population-based screening influenced the subsequent U.S. Preventive Services Task Force (USPSTF) recommendation against routine PSA screening. The USPSTF did not address DRE. Therefore, the authors have evaluated the prognostic value of abnormal DRE and PSA following the widespread use of PSA testing. They assessed the association of suspicious DRE and abnormal PSA with the detection of clinically significant prostate cancer, prostate cancer mortality and overall mortality. The data showed that suspicious DRE and abnormal PSA were significantly associated with clinically significant prostate cancer. There was only moderate agreement between PSA and DRM in each screening encounter. The authors emphasized the continued role of DRE and PSA and need for additional research to optimize screening protocols.http://jurolsurgery.org/article_14738/Re-Prognostic-Significance-Of-Digital-Rectal-Examination-And-Prostate-Specific-Antigen-In-The-Prostate-Lung-Colorectal-And-Ovarian-plco-Cancer-Screening-Arm
spellingShingle Özgür Yaycıoğlu
Re: Prognostic Significance of Digital Rectal Examination and Prostate Specific Antigen in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Arm
Journal of Urological Surgery
title Re: Prognostic Significance of Digital Rectal Examination and Prostate Specific Antigen in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Arm
title_full Re: Prognostic Significance of Digital Rectal Examination and Prostate Specific Antigen in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Arm
title_fullStr Re: Prognostic Significance of Digital Rectal Examination and Prostate Specific Antigen in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Arm
title_full_unstemmed Re: Prognostic Significance of Digital Rectal Examination and Prostate Specific Antigen in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Arm
title_short Re: Prognostic Significance of Digital Rectal Examination and Prostate Specific Antigen in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Arm
title_sort re prognostic significance of digital rectal examination and prostate specific antigen in the prostate lung colorectal and ovarian plco cancer screening arm
url http://jurolsurgery.org/article_14738/Re-Prognostic-Significance-Of-Digital-Rectal-Examination-And-Prostate-Specific-Antigen-In-The-Prostate-Lung-Colorectal-And-Ovarian-plco-Cancer-Screening-Arm
work_keys_str_mv AT ozguryaycıoglu reprognosticsignificanceofdigitalrectalexaminationandprostatespecificantigenintheprostatelungcolorectalandovarianplcocancerscreeningarm